Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2)

被引:84
|
作者
Zolk, Oliver [1 ]
Solbach, Thomas F. [1 ]
Koenig, Joerg [1 ]
Fromm, Maring F. [1 ]
机构
[1] Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany
基金
芬兰科学院;
关键词
Organic cation transporter; Topological polar surface area; Pharmacophore; RENAL TRANSPORTERS; TUBULAR SECRETION; P-GLYCOPROTEIN; SURFACE-AREA; HUMAN KIDNEY; BINDING; METFORMIN; HOCT1; DRUGS; EXPRESSION;
D O I
10.1007/s00210-008-0369-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The organic cation transporter 2 (OCT2) provides an important pathway for the uptake of cationic compounds in the kidney, which is the essential step in their elimination from the organism. Although many drugs have been identified which interact with human OCT2, structural elements required for an interaction with OCT2 are not well defined. To address this issue, HEK293 cells stably expressing human OCT2 were generated. IC(50) values of commonly used drugs for inhibition of [(3)H] MPP+ uptake were determined and correlated with physicochemical descriptors. We found only a significant correlation between the topological polar surface area (TPSA) and IC(50) values (r = 0.71, p< 0.0001). Structural alignment of most potent inhibitor drugs of OCT2-mediated MPP(+) uptake was used to construct a two-point pharmacophore consisting of an ion-pair interaction site and a hydrophobic aromatic site separated by 5.0 angstrom. Taken together, our data identify structural determinants for inhibitor interactions with OCT2.
引用
收藏
页码:337 / 348
页数:12
相关论文
共 50 条
  • [21] Characterization of ligand-induced thermal stability of the human organic cation transporter 2 (OCT2)
    Maane, Max
    Xiu, Fangrui
    Bellstedt, Peter
    Kullak-Ublick, Gerd A.
    Visentin, Michele
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [22] Interaction of cisplatin with human organic cation transporter OCT2.
    Filipski, K. K.
    Loos, W. J.
    Verweij, J.
    Sparreboom, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S17 - S18
  • [23] FUNCTIONAL CHARACTERIZATION OF ETHAMBUTOL BY ORGANIC CATION TRANSPORTER 2 (OCT2), IN VITRO.
    Shin, H.
    Lee, Y.
    Choi, H.
    Lim, S.
    Cho, M.
    Yoon, Y.
    Lee, D.
    Masud, P. Md.
    Jung, J.
    Shin, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S96 - S96
  • [24] Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat
    Yonezawa, A
    Masuda, S
    Nishihara, K
    Yano, I
    Katsura, T
    Inui, K
    BIOCHEMICAL PHARMACOLOGY, 2005, 70 (12) : 1823 - 1831
  • [25] A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2)
    Zhang, XH
    Shirahatti, NV
    Mahadevan, D
    Wright, SH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (41) : 34813 - 34822
  • [26] Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants
    Fujita, T
    Urban, TJ
    Leabman, MK
    Fujita, K
    Giacomini, KM
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (01) : 25 - 36
  • [27] Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin
    Eriko Shikata
    Rei Yamamoto
    Hiroshi Takane
    Chiaki Shigemasa
    Tadasu Ikeda
    Kenji Otsubo
    Ichiro Ieiri
    Journal of Human Genetics, 2007, 52 : 117 - 122
  • [28] Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin
    Shikata, Eriko
    Yamamoto, Rei
    Takane, Hiroshi
    Shigemasa, Chiaki
    Ikeda, Tadasu
    Otsubo, Kenji
    Ieiri, Ichiro
    JOURNAL OF HUMAN GENETICS, 2007, 52 (02) : 117 - 122
  • [29] Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
    Filipski, K. K.
    Mathijssen, R. H.
    Mikkelsen, T. S.
    Schinkel, A. H.
    Sparreboom, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (04) : 396 - 402
  • [30] Human Organic Cation Transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as Disposition Pathways for Fluoroquinolone Antimicrobials
    Mulgaonkar, Aditi
    Venitz, Juergen
    Gruendemann, Dirk
    Sweet, Douglas H.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) : 2705 - 2711